Nasdaq -- PARIS -(Dow Jones)- French pharmaceutical giant Sanofi-Aventis SA (SNY) is considering "strategic alternatives" for its U.S. dermatology business, a company spokeswoman said Thursday. The company is "exploring strategic alternatives for the U.S. dermatology business in keeping with its strategy of relocating resources to high-growth areas," she told Dow Jones Newswires, citing areas of diabetes, oncology, and atrial fibrillation.
